• Molecular NameEthchlorvynol
  • SynonymAethyl-chlorvynol; Etchlorvinolo; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethclorvynol; Ethochlorvynol; Ethychlorvynol
  • Weight144.601
  • Drugbank_IDDB00189
  • ACS_NO113-18-8
  • Show 3D model
  • LogP (experiment)1.74
  • LogP (predicted, AB/LogP v2.0)1.7
  • pkaN/A
  • LogD (pH=7, predicted)1.7
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.66
  • LogSw (predicted, AB/LogsW2.0)4.62
  • Sw (mg/ml) (predicted, ACD/Labs)3.15
  • No.of HBond Donors1
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds3
  • TPSA20.23
  • StatusFDA approved, US withdrawn
  • AdministrationN/A
  • PharmacologyA sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed after oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding42.5
  • Volume of distribution (VD)2~3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, about 1.1.
  • MetabollsmIt is extensively metabolised; the major metabolite found in the blood and urine of poisoned patients is 1-chloro-3-ethynylpent-1-ene-3,4-diol; other metabolites include 1-chloro-3-ethynylpent-1-ene-3,5-diol and 1-chloro-3-ethylpent-1-ene-3,4-diol. Ethchlorvynol is highly localised in the tissues, particularly in adipose tissue, and is released very slowly.
  • Half lifeDistribution half-life, about 1 to 3 h and elimination half-life of 10 to 20 h, increased in overdose cases.
  • ExcretionLess than 0.1% of a dose is excreted in the urine in 24 h as unchanged drug or its glucuronide conjugate. Ethchlorvynol crosses the placenta.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe estimated minimum lethal dose is 15 g, although death has occurred after the acute ingestion of 2.5 g. Plasma concentrations greater than about 20 mg/L are associated with toxic effects. Prolonged use of ethchlorvynol may lead to dependence of the barbiturate–alcohol type.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A